Methods and vaccines for inducing immune responses to multiple different MHC molecules

Abstract

This document provides methods and materials relating to isolated polypeptides, polypeptide preparations, vaccine preparations (e.g., anti-cancer vaccine preparations), and methods for vaccinating mammals. For example, polypeptides (e.g., CMV, MUC1, HER2, Mesothelin (MESO), TRAG-3, or CALR polypeptides) having the ability to be processed into different polypeptides such that the processed polypeptides as a group are capable of being presented by different MHC molecules present in a particular mammalian population are provided.

Claims

1. A composition comprising at least one isolated polypeptide, wherein the amino acid sequence of said at least one isolated polypeptide consists of the amino acid sequence set forth in any one of SEQ ID NOs:1-58, wherein (a) said polypeptide is amidated at the C-terminus or acetylated at the N-terminus, (b) said composition further comprises an adjuvant, or (c) both (a) and (b).

2. The composition of claim 1, wherein said polypeptide is amidated at the C-terminus and/or acetylated at the N-terminus.

3. The composition of claim 1, wherein said composition further comprises an adjuvant.

4. The composition of claim 1, wherein the amino acid sequence of said at least one isolated polypeptide consists of the amino acid sequence set forth in any one of SEQ ID NOs:1-52.

5. A method of treating a mammal having cancer comprising cancer cells expressing an antigen or a precancerous condition comprising precancerous cells expressing said antigen, wherein said method comprises administering to said mammal a composition comprising an adjuvant and at least one polypeptide, wherein the amino acid sequence of said polypeptide consists of the sequence set forth in any one of SEQ ID NOs:1-58, and wherein said antigen comprises said amino acid sequence.

6. The method of claim 5, wherein said mammal is a human.

7. The method of claim 5, wherein said cancer is breast cancer, pancreatic cancer, ovarian cancer, stomach cancer, lung cancer, colon cancer, multiple myeloma, leukemia, brain cancer, or melanoma cancer.

8. The method of claim 5, wherein said precancerous condition is primary myelofibrosis, essential thrombocythemia, or polycythemia vera.

9. The method of claim 5, wherein said adjuvant is CpG, aluminum sulfate, aluminum phosphate, MF59, Pam3CSK4, LPS, polyIC, imiquimod, or R848.

10. The method of claim 5, wherein said polypeptide is amidated at the C-terminus and/or acetylated at the N-terminus.

11. The method of claim 5, wherein the amino acid sequence of said polypeptide consists of the sequence as set forth in any one of SEQ ID NOs: 1-52.

12. A method of inducing an immune response against at least one polypeptide, wherein the sequence of said polypeptide consists of the sequence set forth in any one of SEQ ID NOs:1-58, wherein said method comprises administering said polypeptide to a mammal in an amount effective to induce an immune response against said polypeptide.

13. The method of claim 12, wherein said polypeptide is administered in combination with an adjuvant.

14. The method of claim 13, wherein said adjuvant is CpG, aluminum sulfate, aluminum phosphate, MF59, Pam3CSK4, LPS, polyIC, imiquimod, or R848.

15. The method of claim 12, wherein said polypeptide is amidated at the C-terminus and/or acetylated at the N-terminus.

16. The method of claim 12, wherein the sequence of said polypeptide consists of the sequence set forth in any one of SEQ ID NOs:1-52.

Description

DESCRIPTION OF DRAWINGS

(1) FIG. 1 illustrates promising MHC binding peptide epitopes identified using the program “SYFPEITHI.” The illustration analyzes the full the amino acid sequence for the protein MUC1 (SEQ ID NO:76). The part of the sequence located inside the box represents the variable number of tandem repeats domain (VNTR). Each sequence underlined and labeled with “#” is predicted to bind to the limited number (six) of HLA-DR molecules that are included in the SYFPEITHI algorithm. Each sequence underlined and labeled with “##” is predicted to bind to HLA-A2, as predicted by the SYFPEITHI algorithm. Areas labeled with “{circumflex over ( )}” have both HLA-DR and HLA-A2 predicted epitopes. The numbers beside represent SYFPEITHI arbitrary binding scores+/− standard deviation for the HLA-DR types tested by SYFPEITHI. This type of analysis has been employed to synthesize peptides 15-17 amino acids long which can directly bind to HLA-DRB1 (MHC Class II) molecules, as well as peptides 8-9 amino acids long which can directly bind to HLA-A2 (MHC Class I) molecules.

(2) FIGS. 2A-2C are results from an antigen discovery algorithm. FIG. 2A is the amino acid sequence for a MUC1 polypeptide (SEQ ID NO:77). Each amino acid is shaded based upon the frequency of HLA-DRB1 (MHC Class II) molecules that epitope is predicted to bind. Epitopes begin with the shaded-coded amino acid and are 15 amino acids long. “Dead” epitopes are light in shade and range to darker for epitopes with a high frequency of binding. This allows for a graphical “heat map” of the immunogenic regions within polypeptides and graphically represents the advancement over other techniques for the polypeptides described herein. FIG. 2B is a similarly derived “heat map” of a human HER2 polypeptide (SEQ ID NO:78) with a similar scale to graphically represent “hot spots” of epitopes displaying affinity for multiple MHC Class II molecules. FIG. 2C is a heat map of a 40 aa C-terminal neo-epitope of a human calreticulin (CALR) polypeptide (SEQ ID NO:79).

(3) FIG. 3 is a graph plotting the average predicted affinities (IC.sub.50) for cleavable 15-mer epitopes within SEA1, SEA2, VNTR1, and CMV pp65 polypeptides.

(4) FIG. 4A is a dot plot from an intracellular cytokine assay, plotting interferon gamma (IFNγ) levels of T-cells in response to different restimulatory conditions after T-cell cultures were initially stimulated with the CMV pp65 polypeptide. To control for background levels of IFNγ, T-cells were tested against a lack of polypeptide or an irrelevant MUC1 polypeptide. FIG. 4B is a dot plot from an intracellular cytokine assay plotting IFNγ levels of T-cells in response to different restimulatory conditions after T-cell cultures were initially stimulated with the SEA2 polypeptide. To control for background levels of IFNγ, T-cells were tested against a lack of polypeptide or an irrelevant CMV and irrelevant MUC1 polypeptide. FIGS. 4C and 4D are graphs plotting the frequency of antigen-specific CD4.sup.+ T cells and CD8.sup.+ T cells, respectively, as measured by the percentage of T-cells, which secrete antigen-specific IFNγ. Briefly, T-cell cultures from four different healthy donors were initially stimulated with one of four polypeptides, CMV pp65, VNTR1, SEA1, or SEA2. At the end of culture, T-cells were restimulated with the original polypeptide and other irrelevant polypeptides or no polypeptide. Each data point represents the level of IFNγ after subtracting the levels of IFNγ from restimulation with irrelevant polypeptides or no polypeptide from levels when T-cells were restimulated with the original polypeptide.

(5) FIG. 5A is a dot plot from an intracellular cytokine assay, plotting IFNγ levels of T-cells in response to different restimulatory conditions after T-cell cultures were initially stimulated with the HER2/neu-derived p146-74 peptide sequences. FIG. 5B is a dot plot from an intracellular cytokine assay, plotting IFNγ levels of T-cells in response to different restimulatory conditions after T-cell cultures were initially stimulated with the HER2/neu-derived p845-65 peptide sequences. FIG. 5C is a dot plot from an intracellular cytokine assay, plotting IFNγ levels of T-cells in response to different restimulatory conditions after T-cell cultures were initially stimulated with the HER2/neu-derived p675-703 peptide sequences. FIG. 5D is a dot plot from an intracellular cytokine assay, plotting IFNγ levels of T-cells in response to different restimulatory conditions after T-cell cultures were initially stimulated with the HER2/neu-derived p776-97 peptide sequences.

(6) FIG. 6 is a series of graphs plotting percentage of lysis in T-cells from cultures driven polyclonally with anti-CD3/CD28 (left), driven by long peptides sequenced from the SEA1 domain of MUC1 (middle), or driven by long peptides sequenced from the SEA2 domain of MUC1 (right). At the end of T-cell culture expansion, each of the T-cell groups was transduced to express MUC1 (MDA-MB-231.MUC1) or Neo control (MDA-MB-231.Neo). SEA1- and SEA2-driven T-cells from all 3 donors (represented by triangles, circles, or squares) lysed MDA-MB-231.MUC1 targets significantly more than MDA-MB-231.Neo targets (two-tailed p=0.039 and 0.038 applying Student's paired t-test).

(7) FIG. 7 is a series of dot plots from intracellular cytokine assays, plotting IFNγ levels of T-cells cultured from unfractionated PBMC from a patient with advanced breast cancer in response to different restimulatory conditions (unpulsed, or pulsed with a cocktail of SEA1, SEA2, SEA3, or CMV peptides).

(8) FIG. 8 is a graph plotting the percentage of antigen (Ag) specific IFNγ T cells in fresh and recryopreserved T cells stimulated with either CMVpp65 or SEA1 peptides. The percentage of CD4.sup.+ and CD8.sup.+ T-cells making IFNγ upon specific reexposure to CMVpp65 or SEA1 is shown. Data is representative of three biological replicates.

(9) FIG. 9 is a graph plotting the percentage of Ag-specific IFNγ T cells stimulated with different concentrations of SEA1 peptides with (SEAL-amide) or without C-terminal amidation.

DETAILED DESCRIPTION

(10) This document provides isolated polypeptides, polypeptide preparations, vaccine preparations (e.g., anti-cancer vaccine preparations), and methods for vaccinating mammals. For example, this document provides polypeptides that have the ability to be naturally processed and presented by different MHC molecules. In some cases, a polypeptide provided herein can have a sequence present in a cancer antigen polypeptide such as a MUC1, HER2, MESO, TRAG-3, or CALR polypeptide.

(11) In general, a polypeptide provided herein is a fragment of a full-length polypeptide that is longer than 18 amino acid residues in length and shorter than the full length polypeptide. For example, a polypeptide provided herein can range from about 18 to about 55 (e.g., about 18 to about 50, about 20 to about 50, about 25 to about 50, about 30 to about 50, about 18 to about 45, about 18 to about 40, about 18 to about 35, about 20 to about 45, about 25 to about 40, or about 30 to about 35) amino acid residues in length. In some cases, a polypeptide provided herein can have the ability to induce immune responses in the context of multiple different MHC molecules. Examples of polypeptides provided herein include, without limitation, the polypeptides set forth in SEQ ID NOs:1-58 (Table 1).

(12) TABLE-US-00001 TABLE 1 Examples of immunogenic polypeptides. SEQ ID Testing/ NO: Details Amino acid sequence (length)  1 */CMV  SQEPMSIYVYALPLKMLNIPSINVHHYP  pp65 (28 aa)  2 MUC1 (N- VPSSTEKNAVSMTSSVLSSHSPGSGSSTTQGQ  terminus (32 aa) domain)  3 */MUC1 NRPALGSTAPPVHNVTSASGSASGSASTLV  (degen- (30 aa) erate repeat domain)  4 MUC1 STAPPVHNVTSASGSASGSASTLVHNGTSARATTTPA  (degen- (37 aa) erate repeat domain)  5 */MUC1 STSPQLSTGVSFFFLSFHISNLQFNSSLEDPSTD  (SEA1 (34 aa) domain)  6 */MUC1 STDYYQELQRDISEMFLQIYKQGGFLGLSNIKFRPGS  (SEA2 VV (39 aa) domain)  7 */MUC1 VHDVETQFNQYKTEAASRYNLTISDVSVSDVPFP  (SEA3 (34 aa) domain)  8 HER2 MELAALCRWGLLLALLPPGAASTQVCT (27 aa)  9 HER2 PASPETHLDMLRHLYQGCQVVQGNLELT (28 aa) 10 HER2 VVQGNLELTYLPTNASLSFLQDIQEV (26 aa) 11 ¶/HER2 LSFLQDIQEVQGYVLIAHNQVRQVPLQRL (29 aa) 12 ¶/HER2 AHNQVRQVPLQRLRIVRGTQLFEDNYALA (29 aa) 13 ¶/HER2 TEILKGGVLIQRNPQLCYQDTILWKDIFH (29 aa) 14 ¶/HER2 YQDTILWKDIFHKNNQLALTLIDTNRSRACHPC  (33 aa) 15 HER2 LGMEHLREVRAVTSANIQEFAGC (23 aa) 16 ¶/HER2 NIQEFAGCKKIFGSLAFLPESFDGDP (26 aa) 17 ¶/HER2 VFETLEEITGYLYISAWPDSLPDLSV (26 aa) 18 ¶/HER2 DLSVFQNLQVIRGRILHNGAYSLTLQGLG (29 aa) 19 HER2 TLQGLGISWLGLRSLRELGSGLALIHHN (28 aa) 20 ¶/HER2 ELGSGLALIHHNTHLCFVHTVPW (23 aa) 21 HER2 HNTHLCFVHTVPWDQLFRNPH (21 aa) 22 HER2 PSGVKPDLSYMPIWKFPDEEG (21 aa) 23 HER2 EQRASPLTSIISAVVGILLVVV (22 aa) 24 ¶/HER2 IKRRQQKIRKYTMRRLLQETELVEPLTPS (29 aa) 25 HER2 QAQMRILKETELRKVKVLGSGAFGTVYK (28 aa) 26 ¶/HER2 GVGSPYVSRLLGICLTSTVQLVTQLM (26 aa) 27 HER2 DLLNWCMQIAKGMSYLEDVRL (21 aa) 28 HER2 LEDVRLVHRDLAARNVLVKSP (21 aa) 29 ¶/HER2 DLAARNVLVKSPNHVKITDFG (21 aa) 30 ¶/HER2 DGGKVPIKWMALESILRRRFTHQS (24 aa) 31 HER2 ESILRRRFTHQSDVWSYGV (19 aa) 32 HER2 RLPQPPICTIDVYMIMVKCWMIDSECR (27 aa) 33 ¶/HER2 SECRPRFRELVSEFSRMARDPQRFVVIQ (28 aa) 34 HER2 ARDPQRFVVIQNEDLGPASP (20 aa) 35 MESO ALGSLLFLLFSLGWVQPSRTLAGETGQ (27 aa) 36 MESO GLSTERVRELAVALAQKNVKLSTEQLR (27 aa) 37 MESO LDALPLDLLLFLNPDAFSGPQAC (23 aa) 38 MESO FLNPDAFSGPQACTRFFSRITKANVDLLPRGAP  (33 aa) 39 MESO PSTWSVSTMDALRGLLPVLGQPIIRSIPQGIVAAWR QRSSRDPS (44 aa) 40 MESO PSTWSVSTMDALRGLLPVLGQPIIRSIPQG  (30 aa) 41 MESO ALRGLLPVLGQPIIRSIPQGIVAAWRQRSSRDPS  (34 aa) 42 MESO PSTWSVSTMDALRGLLPVLGQPIIRSIPQGIVAAWR QRSSRDPS (44 aa) 43 MESO QGYPESVIQHLGYLFLKMSPEDIRKWNVT (29 aa) 44 MESO PEDIRKWNVTSLETLKALLEVNKGH (25 aa) 45 MESO NMNGSEYFVKIQSFLGGAPTED (22 aa) 46 MESO SQQNVSMDLATFMKLRTDAVLPLTVAEV (28 aa) 47 MESO SQQNVSMDLATFMKLRTDAVLPLTVAE (27 aa) 48 MESO DAVLPLTVAEVQKLLGPHVEGLKAE (25 aa) 49 MESO GGIPNGYLVLDLSMQEALSGTPCLLGPGPV  (30 aa) 50 TRAG-3 MWMGLIQLVEGVKRKDQGFLE (21 aa) 51 TRAG-3 GFLEKEFYHKTNIKMRCEFLACWPAFTVLGEA  (32 aa) 52 TRAG-3 DQVDWSRLLRDAGLVKMSRKPRASSPLSN (29 aa) 53 CALR  RRMMRTKMRMRRMRRTRRKMSPARPRTSCREACLQG  neo- WTEA (40 aa) epitope 54 CALR  RRMMRTKMRMRRMRRTRRKMSPAR (24 aa) neo- epitope 55 CALR  RRMMRTKMRMRRMRRTRR (18 aa) neo- epitope 56 */MUC1 SPQLSTGVSFFFLSFHISNLQFNSSLEDPSTD  (SEA1 (32 aa) domain) 57 ¶/HER2 GVGSPYVSRLLGICLTSTVQLV (22 aa) 58 MUC1- AHGVTSAPDTRPAPGSTAPPAHGV (24 aa) VNTR * Represents polypeptides confirmed to be immunogenic in 4/4 healthy donors. ¶ Represents polypeptides confirmed to be immunogenic in one healthy donor.

(13) The term “isolated” refers to material which is substantially or essentially free from components which normally accompany the material as it is found in its native state. Thus, isolated polypeptides as described in this document do not contain at least some of the materials normally associated with the polypeptides in their in situ environment. The term “polypeptide” refers to a chain of amino acids linked by polypeptide bonds.

(14) Any appropriate method can be used to obtain a polypeptide provided herein. For example, polypeptides having the sequence set forth in any one of SEQ ID NOs:1-58 can be obtained using polypeptide synthesizing methods. In some cases, a polynucleotide sequence encoding a polypeptide provided herein can be inserted into a plasmid or other vector that can then be delivered to hosts that can be induced to transcribe and translate the polynucleotide into the polypeptide. In some cases, a polynucleotide sequence for a larger polypeptide can be inserted into host cells that can produce the larger polypeptide and then process that polypeptide into a smaller polypeptide or a functional variant of interest.

(15) This document also provides compositions (e.g., anti-cancer vaccine compositions) containing one or more polypeptides provided herein. In some cases, a polypeptide provided herein can have the ability to be processed and presented by an MHC molecule. In some cases, the polypeptides set forth in SEQ ID NOs:1-58 can be used individually or as a mixture of two or more polypeptides to produce a composition (e.g., anti-cancer vaccine compositions). Any appropriate combination of the polypeptides listed in Table 1 can be used to produce a composition (e.g., anti-cancer vaccine compositions). For example, the combination can include at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or more polypeptides selected from Table 1. For example, the polypeptides corresponding to SEQ ID NOs:2-7 can be used in any combination to produce an anti-cancer vaccine composition. In some cases, the polypeptides corresponding to SEQ ID NOs:2-7 and SEQ ID NOs:35-49 can be used in any combination to produce an anti-cancer vaccine composition. In some cases, a polypeptide having the amino acid sequence set forth in SEQ ID NO:2 and a polypeptide having the amino acid sequence set forth in SEQ ID NO:4 can be used together in any combination with one or more polypeptides of SEQ ID NOs:8-34 to produce an anti-cancer vaccine composition.

(16) In some cases, a polypeptide provided herein (e.g., a polypeptide presented in Table 1) can include oxidized amino acid residues (e.g., oxidized forms of methionine) or can lack oxidized amino acid residues.

(17) In some cases, a polypeptide provided herein (e.g., a polypeptide presented in Table 1) can include one or more modifications (e.g., post-translational modifications). Examples of post-translational modifications that can be present on a polypeptide provided herein include, without limitation, amidation (e.g., C-terminal amidation), acetylation (e.g., N-terminal acetylation), glycosylation, phosphorylation, and lipidation. For example, any one of SEQ ID NOs:1-58 can be amidated at the C-terminus and/or acetylated at the N-terminus. In cases where a mixture of two or more polypeptides provided herein are used, each polypeptide can be independently modified. For example, a combination of two or more of SEQ ID NOs:1-58 can include unmodified polypeptides, polypeptides amidated at the C-terminus, polypeptides acetylated at the N-terminus, and/or polypeptides amidated at the C-terminus and acetylated at the N-terminus.

(18) A composition provided herein containing one or more polypeptides set forth in SEQ ID NOs:1-58 or any appropriate combination of polypeptides as described herein can be formulated to provide a polypeptide-based, anti-cancer vaccine. Any appropriate method can be used to formulate a polypeptide-based vaccine including, for example, those methods used to formulate polypeptide-based vaccines directed against other targets. Examples of polypeptide-based vaccines directed to other targets are described elsewhere (see, e.g., Belyakov et al., Proc. Natl. Acad. Sci. U.S.A., 95(4):1709-1714 (1998) and Jackson et al., Proc. Natl. Acad. Sci. U.S.A., 101(43):15440-15445 (2004)).

(19) In some cases, a composition provided herein can be designed to treat cancer or a precancerous condition. For example, a composition (e.g., a vaccine composition) provided herein can have the ability to induce a therapeutic immune response against cancer cells within a mammal (e.g., a human). For example, a composition provided herein can have the ability to activate and, optionally, expand T-cells obtained from a mammal (e.g., a human) in culture.

(20) A polypeptide provided herein (e.g., a polypeptide set forth in Table 1) can be formulated into a vaccine composition using any appropriate method. In some cases, a polypeptide provided herein can be combined with a pharmaceutically acceptable carrier or pharmaceutical excipient. The term “pharmaceutically acceptable” refers to a generally non-toxic, inert, and/or physiologically compatible composition. A term “pharmaceutical excipient” includes materials such as adjuvants, carriers, pH-adjusting and buffering agents, tonicity adjusting agents, wetting agents, preservatives, and the like. Examples of adjuvants include, without limitation, CpG, aluminum sulfate, aluminumphosphylate, MF59, Pam3CSK4, LPS, polyIC, imiquimod, and R848. In some cases, vaccines or components of a vaccine can be conjugated to, for example, a polysaccharide or other molecule, to improve stability or immunogenicity of one or more vaccine components. In some cases, a polypeptide provided herein (e.g., a polypeptide set forth in Table 1) can be formulated into a vaccine composition containing cells. For example, one or more polypeptides provided herein can be included within a cellular vaccine. Any appropriate method can be used to prepare a cellular vaccine or the components of a cellular vaccine.

(21) This document also provides methods and materials (e.g., vaccines) for treating cancer or a precancerous condition. For example, the vaccines provided herein can include one or more of the cancer antigen polypeptides provided herein and can have the ability to induce a therapeutic immune response against cancer cells within a mammal (e.g., a human). For example, the compositions provided herein can include one or more of the cancer antigen polypeptides provided herein and can have the ability to activate and, optionally, expand T-cells obtained from a mammal (e.g., a human) in culture. Activated T-cells can be used in an immunotherapy (e.g., adoptive T-cell therapy), and can be administered to a mammal (e.g., a human) to induce a therapeutic immune response against cancer cells within the mammal. Any appropriate type of cancer can be treated using the methods and materials provided herein. For example, breast cancer, pancreatic cancer, ovarian cancer, stomach cancer, lung cancer, colon cancer, multiple myeloma, leukemia, brain cancer, and melanoma cancer can be treated using the methods and materials provided herein. Any appropriate type of precancerous condition can be treated using the methods and materials provided herein. For example, myelofibrosis (e.g., primary myelofibrosis), essential thrombocythemia, and polycythemia vera can be treated using the methods and materials provided herein.

(22) In some cases, a composition provided herein (e.g., an anti-cancer vaccine composition) can be administered to a mammal having cancer or a precancerous condition under conditions effective to reduce the severity of one or more symptoms of the cancer or precancerous condition and/or to reduce the number of cancer cells or precancerous cells present within the mammal. Treatment of individuals having cancer or a precancerous condition can include the administration of a therapeutically effective amount of one or more polypeptides provided herein (e.g., one or more of SEQ ID NOs:1-58). In some cases, treatment can include the use of one or more polypeptides set forth in SEQ ID NOs:1-58 individually or as a mixture. The polypeptides can be used or administered as a mixture, for example, in equal amounts, or individually, provided in sequence, or administered all at once. The term “therapeutically effective amount” as used with treating cancer or a precancerous condition refers to that amount of the agent sufficient to reduce one or more symptoms of the cancer of precancerous condition and/or to reduce the number of cancer cells or precancerous cells within a mammal. In providing a subject with a polypeptide provided herein (e.g., an anti-cancer vaccine composition) capable of inducing a therapeutic effect, the amount of administered agent will vary depending upon such factors as the subject's age, weight, height, sex, general medical condition, previous medical history, etc. The subject can be, for example, a mammal. The mammal can be any type of mammal including, without limitation, a mouse, rat, dog, cat, horse, sheep, goat, cow, pig, monkey, or human.

(23) The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1—Identification of Long Polypeptides Having Promiscuous MHC Binding Capabilities

(24) There are two classes of MHC molecules: MHC Class I and Class II that are involved in presentation of epitopes to T-cells. CD8.sup.+ T-cells recognize epitopes that are typically 8-12 amino acids long, on MHC Class I. CD4.sup.+ T-cells recognize epitopes that are typically 15-20 amino acids long, on MHC Class II. In order for T-cells to recognize these epitopes, the epitopes have to remain bound to MHC molecules, meaning that the affinity of epitopes for MHC molecules limits which epitopes are part of an immune response.

(25) Within MHC Class I, there are three gene loci, HLA-A, -B, and -C that determine the protein sequence for these MHC Class I molecules, and thus the epitopes that are part of an immune response. While there is genetic diversity in these loci, within the HLA-A locus specifically, nearly 50% of the population has the same gene, HLA-A2. One can identify epitopes that bind to HLA-A2 and use these peptides to therapeutically treat HLA-A2 positive cancer patients, either as part of a vaccine or in another modality.

(26) The MHC Class II gene loci, HLA-DP, -DQ, and -DR are much more genetically diverse. Of these loci, HLA-DR is the most studied, and its role in the presentation of epitopes to CD4.sup.+ T-cells is best understood. HLA-DP and -DQ may have more specific roles that are not well suited for all situations where epitopes are presented to CD4.sup.+ T-cells. Within the DR locus, the significant genetic diversity is attributable to diversity of HLA-DRB1 genes. Furthermore, specific HLA-DRB1 genes are associated with additional HLA-DRB genes (HLA-DRB3,4,5), which further diversify the repertoire of MHC Class II molecules in the population.

(27) The strategy employed by HLA-A2 epitope identification may not work for HLA-DR; epitopes should bind to multiple HLA-DR types in order to be used rationally to treat cancer patients.

(28) Initial investigations utilized a binding prediction algorithm SYFPEITHI, which scans only six HLA-DR types (HLA-DRB*0101, *0301, *0401, *0701, *1101 & *1501) and assigns arbitrary scores to epitopes based upon amino acids that are known to assist in the binding to MHC molecules. As an example, shown in FIG. 1, the entire sequence of the tumor associate antigen MUC1 was analyzed. Sequences underlined and labeled with (“#”) were predicted to be binders to the HLA-DR types analyzed by SYFPEITHI. Scores shown are averages across the HLA-DR types+/− standard deviation. A few critical limitations of this method were identified: 1. The method predicted a large number of epitopes, which would limit throughput and the ability to rationally test all epitopes. 2. The method did not adequately delineate between epitopes in order to determine which should be stronger binders amongst the identified epitopes. 3. Most importantly, it did not encompass a wide enough cross section of HLA types to rationally treat enough patients.

(29) Due to the large number HLA-DR types, it would be onerous to examine all of them to assess, which epitopes bind to the most HLA-DR types. The following was performed to rationally limit the investigation to HLA-DRB1, due to the fact that it is the most well studied HLA-DR molecule, epitope binding prediction algorithms were largely trained on HLA-DRB1 molecules, and the fact that HLA-DRB3, 4, and 5 only occur in conjunction with specific HLA-DRB1 genes.

(30) Utilizing previously published data, the HLA-DRB1 diversity across multiple global ethnic groups resident within the United States was systematically examined. The goal was to ensure that nearly 9 in 10 patients across the seven main ethnic/racial groups would have HLA-DRB1 coverage. The following steps recapitulate the methodology: 1. HLA-DRB1 alleles with greater than 6% frequency in 1 or more population groups were chosen. 2. HLA-DRB1 alleles with greater than 3% frequency in 2 or more population groups were chosen. 3. HLA-DRB1 alleles with greater than 1.5% frequency in 3 or more population groups were chosen. 4. For population groups with less than 89.0% coverage, add next highest allele frequencies for that group, until 89% coverage.

(31) As indicated in Table 2, 29 different HLA-DRB1 types were chosen that covered nearly 90% of each population, thus ensuring that nearly 9/10 people in the United States could respond. This level of population coverage was unattainable using other technologies.

(32) TABLE-US-00002 TABLE 2 Identification of HLA-DR Alleles Across Races and Ethnicities African DRB1 American Caucasian Chinese Hispanic Indian Japanese Korean Alleles Frequency Frequency Frequency Frequency Frequency Frequency Frequency 0101 2.65% 8.60% 0.93% 4.33% 3.21% 5.84% 5.78% 0102 3.92% 1.38% 0.07% 3.32% 0.13% 0.06% 0.02% 0301 6.99% 12.16%  6.81% 6.95% 7.46% 0.66% 2.20% 0302 6.31% 0.03% 0.00% 0.50% 0.01% 0.01% 0.00% 0401 2.02% 5.78% 0.51% 1.61% 0.90% 1.15% 0.78% 0403 0.17% 0.79% 2.31% 1.84% 5.27% 2.43% 2.57% 0404 0.82% 3.88% 0.88% 5.76% 2.01% 0.32% 1.39% 0405 1.53% 0.67% 6.12% 2.22% 0.75% 14.72%  6.94% 0407 0.39% 1.12% 0.08% 7.47% 0.13% 0.64% 0.44% 0701 10.11%  13.42%  5.31% 9.61% 16.95%  0.94% 7.15% 0802 0.09% 0.08% 0.55% 9.84% 0.51% 4.34% 2.50% 0803 0.04% 0.24% 6.80% 0.27% 0.71% 7.44% 7.62% 0804 5.42% 0.20% 0.01% 0.68% 0.08% 0.02% 0.00% 0901 2.97% 1.03% 15.54%  0.82% 0.94% 13.87%  9.67% 1001 1.92% 0.85% 1.34% 1.30% 6.28% 0.40% 1.70% 1101 8.54% 5.56% 6.26% 3.55% 5.96% 2.58% 4.73% 1104 0.58% 2.95% 0.25% 3.25% 1.97% 0.12% 0.07% 1201 3.82% 1.64% 3.42% 0.91% 0.80% 3.75% 4.83% 1202 0.29% 0.02% 11.50%  0.15% 2.99% 1.71% 3.45% 1301 5.42% 5.63% 0.78% 3.72% 6.73% 0.76% 1.73% 1302 7.30% 4.88% 2.42% 3.50% 3.37% 5.75% 8.62% 1303 3.26% 1.09% 0.02% 1.06% 0.13% 0.04% 0.01% 1401 1.85% 2.61% 3.33% 1.84% 1.13% 3.01% 2.68% 1404 0.05% 0.07% 0.51% 0.03% 7.13% 0.02% 0.06% 1408 0.01% 0.02% 0.02% 4.27% 0.05% 1.42% 0.68% 1501 2.82% 13.46%  10.12%  6.43% 9.02% 8.67% 7.94% 1502 0.23% 0.72% 2.66% 1.17% 10.73%  9.67% 3.18% 1503 11.66%  0.05% 0.00% 0.58% 0.02% 0.01% 0.00% 1602 1.38% 0.15% 4.35% 2.47% 0.67% 0.67% 0.99% Total 92.6% 92.1% 92.9% 89.4% 95.8% 91.0% 89.7% Coverage

(33) In order to examine this number of HLA-DRB1 molecules, different binding algorithm predictors were used. The netMHCII-pan-2.1 and -3.0 algorithms, which can make binding affinity predictions for the 29 HLA-DRB1 molecules under study (Nielsen et al., Immunome Res., 6:9 (2010), and Karosiene et al., Immunogenetics, 65(10):711-724 (2013)) were chosen. Unlike SYFPEITHI, these predictors provided IC.sub.50 binding affinities, allowing for a quantitative assessment of whether or not the 15-mers are likely to be bound to HLA-DRB1 molecules. Utilizing 500 nM or 750 nM as IC.sub.50 binding cut offs, each full length cancer-associated polypeptide (MUC1, HER2, MESO, TRAG-3, and CALR) was scanned for binding to the 29 different HLA-DRB1 molecules.

(34) This method allowed one to solve the first two problems by reducing the number of epitopes needed for study and allowing one to better rank and rationally evaluate the different epitopes. For example, compared to the SYFPEITHI analysis, no HLA-DRB1 binding epitopes were identified within the variable number of tandem repeats (VNTR) domain of MUC1, a region that has been extensively studied. This increases throughput, reduces cost, and allows for more rational experimental designs.

(35) Furthermore, the method provided additional granularity for determining epitopes that are more promiscuous or better binders than others. While almost all the epitopes were comparable to one another in the SYFPEITHI analysis, this new methodology clearly demonstrated that there are high value and low value epitopes within MUC1. An example of this is the SEA2 polypeptide, which contains the greatest density of extremely promiscuous epitopes, such that in the entire polypeptide there is at least one epitope that binds to all 29 HLA-DR molecules studied (Table 3). This level of prioritizing and being able to rationally rank targets is substantial compared to other methods.

(36) In addition, the challenge of HLA-DR diversity in preventing the rational treatment of cancer patients was overcome. This is largely due to focusing on a greater number of HLA-DR molecules, but it was also due to the unexpected clustering of these promiscuous epitopes around one another within the polypeptide sequence. Many of these promiscuously binding epitopes within a polypeptide region were found to bind to a different set of HLA-DRB1 genes than the other epitopes within that region. This represents a lead break through, allowing for regions of polypeptides that are binders for 90% of the population, even if each epitope within that region does not have the same degree of promiscuity.

(37) Additionally, many of the polypeptides described herein, with 90% population coverage for MHC Class II, contained predicted HLA-A2 epitopes. This discovery allows for the rational targeting of both MHC Class I and Class II, with the potential to synthesize one or more long polypeptides (e.g., from 20 to 50 amino acid polypeptides) that encompass these epitopes and rationally treat cancer patients.

(38) TABLE-US-00003 TABLE 3 SEA2 SEQ ID NO Embedded 15 mers Predicted Binding HLA-DRB1 Molecules #Binders/Total 59 DYYQELQRDISEMFL 01.01, 01.02, 03.01, 03.02, 04.01, 04.05, 07.01, 08.03, 18/29 09.01, 10.01, 11.01, 11.04, 12.01, 12.02, 13.01, 13.02, 13.03, 14.06 60 YYQELQRDISEMFLQ 01.01, 01.02, 03.01, 03.02, 04.01, 04.05, 07.01, 08.03, 18/29 09.01, 10.01, 11.01, 11.04, 12.01, 12.02, 13.01, 13.02, 13.03, 14.06 61 YQELQRDISEMFLQI 01.01, 01.02, 03.01, 03.02, 04.01, 04.05, 07.01, 08.03, 16/29 09.01, 11.04, 12.01, 12.02, 13.01, 13.02, 13.03, 14.06 62 DISEMFLQIYKQGGF 01.01, 01.02, 04.04, 04.05, 07.01, 08.03, 08.04, 10.01, 18/29 11.01, 11.04, 12.01, 12.02, 13.03, 14.04, 14.05, 15.01, 15.03, 16.02 63 ISEMFLQIYKQGGFL 01.01, 01.02, 04.01, 04.04, 04.05, 07.01, 08.03, 08.04, 22/29 09.01, 10.01, 11.01, 11.04, 12.01, 12.02, 13.02, 13.03, 14.04, 14.08, 15.01, 15.02, 15.03, 16.02 64 SEMFLQIYKQGGFLG 01.01, 01.02, 04.01, 04.04, 04.05, 07.01, 08.03, 08.04, 23/29 09.01, 10.01, 11.01, 11.04, 12.01, 12.02, 13.01, 13.03, 14.01, 14.04, 14.06, 15.01, 15.02, 15.03, 16.02 65 EMFLQIYKQGGFLGL 01.01, 01.02, 04.01, 04.04, 04.05, 07.01, 08.03, 08.04, 23/29 09.01, 10.01, 11.01, 11.04, 12.01, 12.02, 13.01, 13.03, 14.01, 14.04, 14.06, 15.01, 15.02, 15.03, 16.02 66 MFLQIYKQGGFLGLS 01.01, 01.02, 04.01, 04.04, 04.05, 07.01, 08.03, 08.04, 23/29 09.01, 10.01, 11.01, 11.04, 12.01, 12.02, 13.01, 13.03, 14.01, 14.04, 14.06, 15.01, 15.02, 15.03, 16.02 67 FLQIYKQGGFLGLSN 01.01, 01.02, 07.01, 08.03, 08.04, 09.01, 10.01, 11.01, 19/29 11.04, 12.01, 12.02, 13.01, 13.03, 14.04, 14.06, 15.01, 15.02, 15.03, 16.02 68 LQIYKQGGFLGLSNI 01.01, 01.02, 04.01, 04.05, 07.01, 08.03, 08.04, 09.01, 19/29 10.01, 11.01, 11.04, 12.01, 12.02, 13.01, 13.03, 14.06, 15.01, 15.03, 16.02 69 QIYKQGGFLGLSNIK 01.01, 01.02, 04.01, 04.05, 08.03, 09.01, 10.01, 11.01, 18/29 11.04, 12.01, 12.02, 13.01, 13.03, 14.06, 15.01, 15.02, 15.03, 16.02 70 IYKQGGFLGLSNIKF 01.01, 01.02, 04.01, 04.04, 04.05, 07.01, 08.03, 09.01, 20/29 10.01, 11.01, 11.04, 12.01, 12.02, 13.03, 14.04, 14.06, 15.01, 15.02, 15.03, 16.02 71 YKQGGFLGLSNIKFR 01.01, 01.02, 04.01, 04.04, 04.05, 04.07, 07.01, 08.03, 24/29 08.04, 09.01, 10.01, 11.01, 11.04, 12.01, 12.02, 13.01, 13.02, 13.03, 14.04, 14.06, 15.01, 15.02, 15.03, 16.02 72 KQGGFLGLSNIKFRP 01.01, 01.02, 03.01, 04.01, 04.03, 04.04, 04.05, 04.07, 24/29 07.01, 08.03, 08.04, 09.01, 10.01, 11.01, 11.04, 12.01, 12.02, 13.03, 14.04, 14.06, 15.01, 15.02, 15.03, 16.02 73 QGGFLGLSNIKFRPG 01.01, 01.02, 04.01, 04.04, 04.05, 04.07, 07.01, 08.03, 21/29 08.04, 09.01, 10.01, 11.01, 11.04, 12.01, 12.02, 13.03, 14.04, 14.06, 15.01, 15.02, 15.03, 16.02 74 GFLGLSNIKFRPGSV 01.01, 01.02, 04.01, 04.04, 04.05, 07.01, 08.02, 08.03, 24/29 08.04, 09.01, 10.01, 11.01, 11.04, 12.01, 12.02, 13.01, 13.02, 13.03, 14.04, 14.06, 15.01, 15.02, 15.03, 16.02 75 FLGLSNIKFRPGSVV 01.01, 01.02, 04.01, 04.04, 07.01, 08.02, 08.03, 08.04, 21/29 09.01, 11.01, 11.04, 12.01, 12.02, 13.01, 13.02, 13.03, 14.04, 14.06, 15.01, 15.03, 16.02

(39) The nature distribution of these clusters allowed for a graphical representation of the discovery, utilizing an intelligent “heat map” of activity. For each MHC Class II epitope (generally considered to be 15 amino acids long) within the entire polypeptide, a shading was assigned on a 29 shading gradient scale between light to dark depending on the number of HLA-DRB1 molecules that the epitope was predicted to bind to out of the 29 tested (using the predicted nM affinities). Epitopes with no predicted binding to any HLA-DRB1 molecules remained light, while a 29/29 was dark (e.g., “hot”). The amino acid at the N-terminus of the epitope bears the shade assigned for that epitope. This analysis allowed for a graphical representation of a polypeptide's immunologic “hot spots.” The immunological hot spots for MUC1, HER2/neu, and a myelofibrosis-associated CALR C-terminal epitope are shown in FIGS. 2A, 2B, and 2C. The 40 aa C-terminus of CALR is a neo-epitope that is not present on CALR of healthy individuals, but is present on CALR in 80% of pre-leukemic patients.

(40) For MUC1, the VNTR polypeptide (FIG. 2A, uppermost box) lacked hot spots in contrast to two hot polypeptides (next two boxes) designated as the SEA1 and SEA2 regions. For both MUC1 and HER2, the final 14 amino acids lacked hot spots because the sequences were too short to have a 15-mer epitope that begins with them. With this methodology, long polypeptides (e.g., longer than 20 amino acid residues) were successfully identified for several cancer-associated antigens (e.g., MUC1, HER2/neu, MESO, TRAG-3, and CALR) as containing a high density of promiscuous HLA-DR 15-mer epitopes.

(41) To test the reliability of these results, the immune responses for MUC1 long polypeptides (SEA1 and SEA2) were compared to that generated using a pathogen polypeptide. To do this, the same identification methodology used for the tumor antigen polypeptides was used to identify hot spots in the cytomegalovirus (CMV) pp65 polypeptide. The hot spot sequence that was identified was used as a control as was the previously identified VNTR polypeptide. As shown in FIG. 3, the predicted average binding affinity across the 29 HLA-DRB1 genes for the 15-mer epitopes within the VNTR polypeptide was extremely high (in this case lower represents a lower amount of polypeptide needed to bind, and thus better), whereas the 15-mers embedded in the CMV long polypeptide, SEA1, and SEA2 were extremely low, thus meaning that the epitopes within CMV pp65, SEA1, and SEA2 are much tighter binders.

(42) The SEA polypeptides, CMV long polypeptide, and VNTR polypeptide were tested in a culture system. Briefly, bulk peripheral blood mononuclear cells (PBMC) were thawed and exposed to GM-CSF on day 0 in culture. On day 1, cultures were exposed to the polypeptides (SEA1, SEA2, CMV pp65, or VNTR) and monocyte maturating agents (LPS and R848). On day 2, media was washed out, and the cells were split 1:6 in fresh media containing IL-7 for T-cell expansion. Further splits occurred with simple addition of more media containing IL-7 depending upon acidity of the media between days 7-15. On day 16, an antigen specific restimulation of T-cell cultures was performed utilizing fresh PBMC as the antigen presenting cells. These fresh PBMC were thawed on day 14 and treated the same way as the initial culture on days 0-1, before being used on day 16. At the time of restimulation, an intracellular cytokine assay was performed. The T-cell cultures also were allowed to proliferate for an additional 14 days in media containing IL-7. At the end of culture, day 28, T-cells were further tested with a new intracellular cytokine assay utilizing fresh PBMC, prepared the same way as the PBMC used on day 16 for the first intracellular cytokine assay. Representative dot-plots for IFNγ levels are shown for the CMV pp65 polypeptide and the SEA2 polypeptide, with levels being much lower when T-cells were not restimulated with the same polypeptide they saw at the initiation of culture. As shown in FIGS. 4C and D, in contrast to the VNTR polypeptide, the CMV long polypeptide, SEA1 long polypeptide, and SEA2 long polypeptide consistently exhibited an immune response by antigen specific IFNγ production. Each data point represents the level of IFNγ after subtracting the levels of IFNγ from restimulation with irrelevant polypeptides or no polypeptide from levels when T-cells were restimulated with the original polypeptide.

(43) Other polypeptides as indicated in Table 1 were tested and confirmed to produce detectable immune responses.

Example 2—Expansion of CD4.SUP.+ and CD8.SUP.+ T-Cells with Enriched Specificity for Tumor-Associated Long Synthetic Polypeptides

(44) Whether GM+R848+LPS conditioned PBMC could process exogenous synthetic peptides as effectively as Candida albicans extract (CAN) extract or recombinantly produced HER2-ICD was examined.

(45) The following long peptides were synthesized for immunotargeting: CMVpp65-derived 28mer (SQEPMSIYVYALPLKMLNIPSINVHHYP; SEQ ID NO:1) MUC1-SEA domain-derived 32mer (SEA1; SPQLSTGVSFFFLSFHISNLQFNSSLEDPSTD-amide; the amino acid sequence of which is set forth in SEQ ID NO:56, with a C-terminal amidation) MUC1-SEA domain-derived 39mer (SEA2; STDYYQELQRDISEMFLQIYKQGGFLGLSNIKFRPGSVV-amide; SEQ ID NO:6 with a C-terminal amidation) HER2 p146-174 29mer (TEILKGGVLIQRNPQLCYQDTILWKDIFH; SEQ ID NO:13) HER2 p848-865 21mer (DLAARNVLVKSPNHVKITDFG; SEQ ID NO:29) HER2 p675-703 29mer (IKRRQQKIRKYTMRRLLQETELVEPLTPS; SEQ ID NO:24) HER2 p776-797 22mer (GVGSPYVSRLLGICLTSTVQLV; SEQ ID NO:57)
MUC1-VNTR 24mer (AHGVTSAPDTRPAPGSTAPPAHGV-amide; the amino acid sequence of which is set forth in SEQ ID NO:58, with a C-terminal amidation) also was synthesized as a control for its contrastingly low predicted affinities for HLA-DR and A2.1 (FIG. 3). All peptides were produced to >98% homogeneity as confirmed by mass spectroscopy.

(46) The synthesized long peptides were individually pulsed onto GM+R848+LPS conditioned PBMC cultures established from unvaccinated HLA-A2.1+ healthy volunteers, then expanded in rhIL-7 or rhIL-7+rhIL-2. Within 16 culture days, it was consistently possible to numerically expand and significantly increase the frequency of T-cells with natural specificity for MUC1, HER2, or CMV, both CD4+ and CD8+(FIGS. 4A, 4B, and 5A-5D). The SEA1 and SEA2 MUC1 sequences as well as CMVpp65 were highly immunogenic, whereas the VNTR non-glycosylated sequence was reproducibly less effective (FIGS. 4C and 4D). Proliferation of CD4+ and CD8+ T-cells was indistinguishable, with both subsets retaining their initial proportionality during expansion.

(47) T-cells from GM+R848+LPS conditioned PBMC driven by either SEA2 or SEA1 long peptides not only specifically recognized one or both of these sensitizing peptides at restimulation, but also preferentially lysed the HLA-A2.1+ human breast cancer line MDA-MB-231 transduced to express MUC1 (MDA-MB-231.MUC1) compared to MDA-MB-231.Neo control targets. In contrast, polyclonally propagated PBMC T-cells (driven by anti-CD3/anti-CD28) failed to preferentially lyse MDA-MB-231.MUC1 over MDA-MB-231.Neo (FIG. 6). % Lysis was calculated as ((Experimental Lysis−Spontaneous Cr.sup.51 release)/(Complete Lysis in Triton X-100-Spontaneous Cry′ release))×100. % lysis of MDA-MB-231.Neo was statistically indistinguishable for all 3 donors whether cultures were polyclonally-, SEA1- or SEA2-driven. Polyclonally driven T-cells from all 3 donors lysed MDA-MB-231.MUC1 indistinguishably from MDA-MB-231.Neo. In contrast, SEA1- and SEA2-driven T-cells from all 3 donors lysed MDA-MB-231.MUC1 targets significantly more than MDA-MB-231.Neo targets (two-tailed p=0.039 and 0.038 applying Student's paired t-test).

(48) Preliminary PBMC cultures established from four breast cancer patients indicated that the presently described culture system could be applied successfully to patients with malignancies (FIG. 7). Furthermore, cultures could be conducted in expansile 1 liter vessels at least as effectively as in 24 well cluster plates, and cocktails of long peptides could be employed to simultaneously expand T-cells encompassing a variety of oncoprotein specificities (FIG. 7). Furthermore, T-cells cryopreserved at the end of culture fully retained their capacity for Ag-specific IFNγ production upon subsequent re-thaw.

(49) These results demonstrated that the cocktail sensitized and expanded the patient's T-cells to recognize each of the antigens in the cocktail.

Example 3—Preservation of T-Cell Antigen-Specific IFNγ Secretion

(50) Whether PBMC-derived human T-cells retained their facility for secreting Ag-specific IFNγ after recryopreservation at culture's end was examined.

(51) PBMCs cryopreserved at the time of initial collection were thawed, activated with GM-CSF, pulsed with CMVpp65 or SEA1 peptides, exposed to R848 and LPS, and then expanded to Day 19 in culture with IL-7. T-cells were harvested on Day 19, and half the cells were recryopreserved for 4 hours and re-thawed later that day. “Fresh” vs “Recryopreserved” T-cells were compared in a restimulatory intracellular IFNγ cytokine assay. Each bar shows % of CD4+ or CD8+ T-cells making IFNγ upon specific reexposure to CMVpp65 or SEA1 (subtracting background % IFNγ in the absence of Ag reexposure).

(52) As shown in FIG. 8, the T-cells can be recryopreserved at the end of culture expansion and still react specifically to the sensitizing peptides after they are re-thawed. Thus, already expanded T-cells can be stored recryopreserved for future therapy.

(53) These results demonstrated that culture-expanded T-cells can be cryopreserved for future therapeutic use without losing their ability to secrete IFNγ upon reexposure to the activating antigen.

Example 4—Modification of Long Polypeptides

(54) The effect of post-translational modification on long polypeptides was examined.

(55) Amidated polypeptides were amidated at the C-terminus as described elsewhere (see, e.g., Brinckerhoff et al., Int. J. Cancer 83(3):326-34 (1999)).

(56) For the healthy donor shown in FIG. 9, amidation of the SEA1 C-terminus (SEA1-amide) rendered it far superior for sensitizing SEA1-specific CD4+IFNγ-producing T-cells when this donor's PBMC were conditioned in a standard way with GM-CSF, R848, LPS and IL-7 (FIG. 9). The SEA1-specific CD8+ T-cell response was less affected by amidation. A cocktail of peptides such as SEA1, SEA1-amide, acetyl-SEA1 and acetyl-SEA1-amide can be used to capture a broadened SEA1 response (or similarly for any other peptide).

(57) These results demonstrated that amide modification of the C-terminus can modify the immunogenicity of an antigenic polypeptide.

Example 5—Use of Long Polypeptides Having Promiscuous MHC Binding Capabilities to Treat Cancer

(58) Patients are diagnosed with Stage III breast cancer that is MUC1 positive. Following surgery and appropriate chemotherapy and/or radiation, the patients are given a vaccine containing at least one MUC1 polypeptide described herein (e.g., SEQ ID NOs:2-7) and a TLR-agonist. Examples of TLR-agonists included, without limitation, CpG, aluminum sulfate, aluminum phosphate, MF59, Pam3CSK4, LPS, polyIC, imiquimod, and R848.

(59) Before, during, and after vaccination, a small amount of the patients' blood optionally is harvested through venipuncture to confirm the efficacy of the vaccine. In some cases, the patients are given an anti-PD-1 antibody or an anti-PD-L1 antibody to prevent a robust immune response against the tumor cells from being inhibited. After treatment, the patients are followed for about 10 years to confirm a lack of recurrence.

(60) If recurrence occurs (e.g., metastasis to bones and lungs), white blood cells are withdrawn via leukophoresis, and the patient's T cells are trained and grown at high numbers outside of the body to recognize one or more MUC1 polypeptides described herein. These T cells are then re-infused into the patient to treat the patient's re-occurring cancer. In some cases, the patient is given an anti-PD-1 antibody or an anti-PD-L1 antibody to prevent a robust immune response against the tumor cells from being inhibited.

OTHER EMBODIMENTS

(61) It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.